Free tool
FAERS Monitor: Nexlizet
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 211617 or its brand name (Nexlizet, Bempedoic Acid, Ezetimibe). Reports on generic versions are filed under their own applications.
Reports
719
Serious
155
22% of reports
Hospitalization
62
Death reported
5
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- myalgia62
- arthralgia60
- pain in extremity47
- fatigue38
- muscle spasms36
- headache31
- back pain30
- diarrhoea29
- pain27
- dizziness26
- product dose omission issue26
- drug ineffective24
- rash24
- abdominal pain upper22
- dyspnoea20
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2018 | 1 |
| 2020 | 42 |
| 2021 | 135 |
| 2022 | 93 |
| 2023 | 41 |
| 2024 | 93 |
| 2025 | 171 |
| 2026 | 143 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,440 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| myalgiaSignal | 62 | 10.7 | 8.4 | 538 |
| muscle spasmsSignal | 36 | 5.7 | 4.2 | 137 |
| pain in extremitySignal | 47 | 4.7 | 3.5 | 134 |
| arthralgiaSignal | 60 | 4.2 | 3.3 | 147 |
| back painSignal | 30 | 3.8 | 2.7 | 59 |
| abdominal pain upperSignal | 22 | 3.1 | 2.1 | 30 |
| product dose omission issueSignal | 26 | 2.6 | 1.8 | 24 |
| rash | 24 | 1.6 | 1.1 | 5 |
| dizziness | 26 | 1.5 | 1.0 | 4 |
| headache | 31 | 1.4 | 1.0 | 4 |
| fatigue | 38 | 1.4 | 1.0 | 5 |
| diarrhoea | 29 | 1.3 | 0.9 | 2 |
| pain | 27 | 1.3 | 0.9 | 1 |
| dyspnoea | 20 | 1.0 | 0.7 | 0 |
| drug ineffective | 24 | 0.5 | 0.4 | 10 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.